Genetic Testing Could Cause Anti-selection But Also Have Positive Impact on In-Force Book
Christian Mumenthaler, CEO of Swiss Re, discusses the impact technology may have on longevity risk, and on the life re/insurance industry. Recorded at the 14th Global Ageing Conference in Zurich.
Genetic Testing – What Does the Crystal Ball Really Reveal?
Knowing the basics of genetic testing and its underlying science is the first step in understanding genetic testing’s potential impact on insurance. Genetic testing is best defined as the analysis of DNA, RNA, chromosomes, proteins and metabolites in relation to heritable risks, traits, and conditions.
Genetic Testing and the Power of Knowledge
Genetic information is treated exceptionally carefully but the growing use of predictive tests by consumers raises concern that the results could influence their approach to life insurance.
The Rising Tide of Genetic Data – New Challenges for Life & Health Insurance
The understanding and application of genetic data is redefining medical diagnosis, treatment and prognosis. As this area continues to advance, it’s set to adjust, maybe even to reshape, the Life and Health insurance business model within the next 20 years.
Genetics – a Testing Time for Insurers?
This paper looks at the broader future implications of genetic testing for society, medical professionals and the insurance industry
Personal genomic testing (PGT): The consumer and the Life Insurance Industry
The life insurance industry is being challenged to respond to the new reality of democratized access to personal genomic data against the backdrop of consumer and regulatory concerns around data privacy, consumer equity and genetic determinism, on the one hand, and life insurers’ concerns about information asymmetry during the underwriting process, on the other.
Genetics and Life Insurance - A View into the Microscope of Regulation
The use of genetic information for life, disability, critical illness and long-term care insurance is likely to increase in relevance. This report represents an attempt to understand key aspects of genetics, as well as limitations and controversies of its utilization in life insurance.
Genomics Is Changing the Rules for Underwriting Breast Cancer Patients
We have made great progress in the battle against breast cancer: improved screening and treatment have produced a 30% reduction in mortality over the last two decades. Better still, continued advances in genomics are opening entirely new possibilities that hold the promise of not only improved outcomes, but an eventual cure. For life and health insurers, it is time to reexamine how we underwrite applicants with a history of breast cancer.
Presentations from the 2016 SEHOUA Meeting
Slides from the 2016 SEHOUA Meeting have been posted. They include:
- Betsy Sears – “Young Kids, Old Bodies”
- Dr. Stout – “Drugs and Alcohol – The Landscape”
- Dr. Titcomb - “Red Cell Distribution Width (RDW): An Underappreciated Marker for Increased Mortality
- Mike Clift – “Motor Vehicle Reports and Driving Criticism Trends, Technology and Terminology”
- Dr. Greene - "Prostate Cancer: A Decade of Change"
- Dr. Dave Rengachary - “Advances in Multiple Sclerosis”
- Dr. Rooney – Genetics: A Discussion of How our Genes Impact Mortality”
- Ron Schaber, Philip R. Murphy and Greg Brandner - “Big Data Today and Tomorrow – the drive toward fully underwritten pricing”